CAP-100
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL[1].
Product Specifications
UNSPSC
12352203
Target
CCR
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Purity
99.84
Smiles
[CAP-100]
Molecular Weight
(146.48 kDa)
References & Citations
[1]Cuesta-Mateos C, et al., Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs. 2021 Jan-Dec;13 (1) :1917484.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ZLA44149-01 250 mg
5- (5-Bromo-2-fluorophenyl) -1,3,4-thiadiazol-2-amine
Sign In for Pricing
View Details ZLA44149-02 2.5 g
5- (5-Bromo-2-fluorophenyl) -1,3,4-thiadiazol-2-amine
Sign In for Pricing
View Details